Boston Scientific lands in San Francisco the week it invests $1.5 billion in a TAVR developer

Boston Scientific flew from Hollywood Burbank to San Francisco Bay Oakland on June 17, a 56-minute hop aboard its Challenger 650 (N650BS). The aircraft had spent the previous days tracing a westward arc from Minneapolis through Cincinnati to Southern California.

The short trip arrives the same week Boston Scientific is closing its $1.5 billion investment in MiRus, a privately held developer of the SIEGEL balloon-expandable TAVR system, the company announced May 18. The investment buys a 34% equity stake and an exclusive option to acquire the TAVR business for an additional $3 billion once clinical and regulatory milestones are met, per Boston Scientific's press release and SEC filing. The same week, the company also entered into a $2 billion accelerated share repurchase agreement with JPMorgan, as announced via PR Newswire.

The West Coast swing follows a pattern: Boston Scientific's home base is Hanscom Field near Marlborough, Massachusetts, but its CEO, Mike Mahoney, and senior leadership frequently visit the Twin Cities (KMSP), Cincinnati (KCVG), and the Bay Area, where key partners and investment targets are based. The June 17 movement from Burbank to Oakland suggests either a final meeting with MiRus stakeholders or internal planning sessions ahead of the STAR pivotal trial, which is evaluating the SIEGEL valve in up to 1,025 patients, as described in the company's investor materials.